Xavier Roblin

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

David Laharie, Arnaud Bourreille, Julien Branche et al. · The Lancet · 2012 · 642 citations

Pharmacy, Internal Medicine, Pharmacotherapy +14

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Séverine Vermeire, Stefan Schreiber, Robert Petryka et al. · The Lancet · 2016 · 439 citations

Pharmacy, Clinical Sciences, Pharmacotherapy +13

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study

Yoram Bouhnik, Franck Carbonnel, David Laharie et al. · Gut · 2017 · 333 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +14

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases

Xavier Roblin, Hubert Marotte, Melanie Rinaudo et al. · Clinical Gastroenterology and Hepatology · 2013 · 276 citations

Medicine, Immunology, Pharmacokinetics +16